ATE538091T1 - Tetrahydrocyclopentaäbüindolverbindungen als androgenrezeptormodulatoren - Google Patents

Tetrahydrocyclopentaäbüindolverbindungen als androgenrezeptormodulatoren

Info

Publication number
ATE538091T1
ATE538091T1 AT07844898T AT07844898T ATE538091T1 AT E538091 T1 ATE538091 T1 AT E538091T1 AT 07844898 T AT07844898 T AT 07844898T AT 07844898 T AT07844898 T AT 07844898T AT E538091 T1 ATE538091 T1 AT E538091T1
Authority
AT
Austria
Prior art keywords
tetrahydrocyclopentaäbüindole
compounds
androgen receptor
receptor modulators
modulators
Prior art date
Application number
AT07844898T
Other languages
German (de)
English (en)
Inventor
Konstantinos Gavardinas
Jonathan Edward Green
Prabhakar Kondaji Jadhav
Donald Paul Matthews
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE538091T1 publication Critical patent/ATE538091T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/58[b]- or [c]-condensed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/58[b]- or [c]-condensed
    • C07D209/70[b]- or [c]-condensed containing carbocyclic rings other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
AT07844898T 2006-11-20 2007-11-06 Tetrahydrocyclopentaäbüindolverbindungen als androgenrezeptormodulatoren ATE538091T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86648406P 2006-11-20 2006-11-20
PCT/US2007/083745 WO2008063867A2 (en) 2006-11-20 2007-11-06 Tetrahydrocyclopenta[b] indole compounds as androgen receptor modulators

Publications (1)

Publication Number Publication Date
ATE538091T1 true ATE538091T1 (de) 2012-01-15

Family

ID=39415431

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07844898T ATE538091T1 (de) 2006-11-20 2007-11-06 Tetrahydrocyclopentaäbüindolverbindungen als androgenrezeptormodulatoren

Country Status (36)

Country Link
US (1) US7968587B2 (OSRAM)
EP (1) EP2094658B1 (OSRAM)
JP (1) JP5399259B2 (OSRAM)
KR (1) KR101121471B1 (OSRAM)
CN (1) CN101541749B (OSRAM)
AR (1) AR063559A1 (OSRAM)
AT (1) ATE538091T1 (OSRAM)
AU (1) AU2007324046B2 (OSRAM)
BR (1) BRPI0719092B8 (OSRAM)
CA (1) CA2670340C (OSRAM)
CL (1) CL2007003182A1 (OSRAM)
CO (1) CO6190513A2 (OSRAM)
CR (1) CR10802A (OSRAM)
CY (1) CY1112284T1 (OSRAM)
DK (1) DK2094658T3 (OSRAM)
EA (1) EA015627B1 (OSRAM)
EC (1) ECSP099350A (OSRAM)
ES (1) ES2376048T3 (OSRAM)
HR (1) HRP20120032T1 (OSRAM)
IL (1) IL198410A (OSRAM)
JO (1) JO2800B1 (OSRAM)
MA (1) MA31072B1 (OSRAM)
MX (1) MX2009005251A (OSRAM)
MY (1) MY154547A (OSRAM)
NO (1) NO342531B1 (OSRAM)
NZ (1) NZ576296A (OSRAM)
PE (1) PE20081161A1 (OSRAM)
PL (1) PL2094658T3 (OSRAM)
PT (1) PT2094658E (OSRAM)
RS (1) RS52191B (OSRAM)
SI (1) SI2094658T1 (OSRAM)
TN (1) TN2009000189A1 (OSRAM)
TW (1) TWI398438B (OSRAM)
UA (1) UA98777C2 (OSRAM)
WO (1) WO2008063867A2 (OSRAM)
ZA (1) ZA200903096B (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
BRPI0907844B8 (pt) 2008-02-22 2021-05-25 Radius Health Inc compostos e método para modular um receptor de andrógeno, processos de preparação e composição farmacêutica dos mesmos e seus usos
KR101278788B1 (ko) * 2008-05-16 2013-06-25 일라이 릴리 앤드 캄파니 테트라히드로시클로펜타[b]인돌 안드로겐 수용체 조절제
AR078862A1 (es) 2009-11-13 2011-12-07 Lilly Co Eli Ester isopropilico del acido ((s)-7-ciano-4-((2r,3s)-3-hidroxitetrahidrofuran-2-ilmetil)-1,2,3,4-tetrahidro-ciclopenta(b)indol-2-il)carbamico, composiciones farmaceuticas que lo comprenden y su uso en terapia
EP2531029B1 (en) 2010-02-04 2016-10-19 Radius Health, Inc. Selective androgen receptor modulators
SI2568806T1 (sl) 2010-05-12 2016-09-30 Radius Health, Inc. Režimi zdravljenja
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
EP2621901B1 (en) 2010-09-28 2015-07-29 Radius Health, Inc Selective androgen receptor modulators
WO2012152741A1 (de) 2011-05-10 2012-11-15 Bayer Intellectual Property Gmbh Bicyclische (thio)carbonylamidine
CN103265479B (zh) * 2013-06-14 2017-12-08 南开大学 一种6‑氯甲基烟酸叔丁酯的合成方法
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
SI3122426T1 (sl) 2014-03-28 2023-04-28 Duke University Zdravljenje raka dojk z uporabo selektivnih modulatorjev estrogenskih receptorjev
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
JOP20180072A1 (ar) * 2014-09-11 2019-01-30 Lilly Co Eli علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين
PL3474841T3 (pl) 2016-06-22 2022-07-11 Ellipses Pharma Ltd Sposoby leczenia nowotworu złośliwego piersi ar+
US20180185347A1 (en) 2016-11-16 2018-07-05 Transition Therapeutics (Ireland 2) Limited Tetrahydrocyclopenta[b]indole compounds and phosphodiesterase inhibitors for the treatment of the signs and symptoms of bhp
SI3565542T1 (sl) 2017-01-05 2024-08-30 Radius Pharmaceuticals, Inc. Polimorfne oblike RAD1901-2HCL
IL279853B2 (en) 2018-07-04 2025-01-01 Radius Pharmaceuticals Inc Polymorphic forms of RAD 1901-2HCL
WO2020167855A1 (en) 2019-02-12 2020-08-20 Radius Pharmaceuticals, Inc. Processes and compounds
CN115023225A (zh) * 2020-01-27 2022-09-06 伊尔根制药有限公司 用于治疗肾病的四氢环戊[b]吲哚化合物
US11986461B1 (en) * 2023-08-24 2024-05-21 King Faisal University 3-(1-(3-(dimethylamino)propyl)-4,5-diphenyl-1H-imidazol-2-yl)pyridin-2-ol as an antitumor and antimicrobial compound

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4988820A (en) 1986-02-21 1991-01-29 Bayer Aktiengesellschaft Cycloalkano(1,2-B) indole-sulponamides
GB8924392D0 (en) 1989-10-30 1989-12-20 Bayer Ag Substituted cycloalkano/b/dihydroindole-and-indolesulphonamides
GB9008108D0 (en) 1990-04-10 1990-06-06 Bayer Ag Cycloalkano(b)dihydroindoles and-indolesulphonamides substituted by heterocycles
DE4027278A1 (de) 1990-08-29 1992-03-05 Bayer Ag Heterocyclisch substituierte indolsulfonamide
DE4131346A1 (de) 1991-09-20 1993-03-25 Bayer Ag Indolsulfonamid substituierte dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
WO2001027086A1 (en) * 1999-10-14 2001-04-19 Kaken Pharmaceutical Co., Ltd. Tetrahydroquinoline derivatives
WO2003014082A1 (en) 2001-08-09 2003-02-20 Eli Lilly And Company Cyclopenta ` b ! indole derivatives as spla2 inhibitors
DE10164564B4 (de) 2001-12-14 2007-05-16 Zentaris Gmbh Tetrahydrocarbazolderivate als Liganden für G-Protein gekoppelte Rezeptoren (GPCR)
EP1505061A4 (en) 2002-05-16 2007-08-22 Shionogi & Co CONNECTION WITH PGD-2 RECEPTOR ANTAGONISM
US20060074124A1 (en) 2003-09-12 2006-04-06 Andrew Napper Methods of treating a disorder
US20050245540A1 (en) * 2003-12-09 2005-11-03 Fujisawa Pharmaceutical Co., Ltd. New methods
US7019022B2 (en) 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
AU2005226759A1 (en) * 2004-03-03 2005-10-06 Eli Lilly And Company Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators
JP2008520674A (ja) * 2004-11-22 2008-06-19 スミスクライン ビーチャム コーポレーション Hcvインヒビター
JP2008520742A (ja) 2004-11-23 2008-06-19 ピーティーシー セラピューティクス, インコーポレイテッド Vegf産生の阻害に有用なカルバゾール誘導体、カルボリン誘導体およびインドール誘導体
PA8663501A1 (es) 2005-02-17 2006-11-09 Wyeth Wyeth Derivados de indol, benzotiofeno, benzofurano e indeno cicloalquilcondensados
MX2007015905A (es) 2005-06-24 2008-03-06 Lilly Co Eli Derivados de tetrahidrocarbazol utiles como moduladores de receptor de androgeno (sarm).
US20090022694A1 (en) 2005-10-18 2009-01-22 Distefano Peter Sirt1 inhibition
WO2008019825A1 (en) 2006-08-14 2008-02-21 Santhera Pharmaceuticals (Schweiz) Ag Use of tricyclic indole derivatives for the treatment of muscular diseases
KR101278788B1 (ko) 2008-05-16 2013-06-25 일라이 릴리 앤드 캄파니 테트라히드로시클로펜타[b]인돌 안드로겐 수용체 조절제

Also Published As

Publication number Publication date
IL198410A (en) 2013-09-30
SI2094658T1 (sl) 2012-04-30
MX2009005251A (es) 2009-08-19
MY154547A (en) 2015-06-30
RS52191B (sr) 2012-10-31
AU2007324046B2 (en) 2012-04-05
EA200970500A1 (ru) 2009-10-30
NZ576296A (en) 2011-11-25
US7968587B2 (en) 2011-06-28
CN101541749B (zh) 2013-03-27
UA98777C2 (en) 2012-06-25
NO342531B1 (no) 2018-06-11
EP2094658A2 (en) 2009-09-02
HRP20120032T1 (hr) 2012-02-29
ES2376048T3 (es) 2012-03-08
BRPI0719092B8 (pt) 2021-05-25
US20100069404A1 (en) 2010-03-18
CY1112284T1 (el) 2015-12-09
KR101121471B1 (ko) 2012-02-28
BRPI0719092A2 (pt) 2013-12-03
WO2008063867A3 (en) 2008-07-31
TW200827347A (en) 2008-07-01
JP5399259B2 (ja) 2014-01-29
PL2094658T3 (pl) 2012-05-31
CN101541749A (zh) 2009-09-23
KR20090082229A (ko) 2009-07-29
IL198410A0 (en) 2010-02-17
JP2010510231A (ja) 2010-04-02
CO6190513A2 (es) 2010-08-19
PE20081161A1 (es) 2008-08-15
CA2670340C (en) 2014-05-20
JO2800B1 (en) 2014-03-15
MA31072B1 (fr) 2010-01-04
PT2094658E (pt) 2012-02-22
ECSP099350A (es) 2009-06-30
CR10802A (es) 2009-07-13
AR063559A1 (es) 2009-02-04
TWI398438B (zh) 2013-06-11
EP2094658B1 (en) 2011-12-21
AU2007324046A1 (en) 2008-05-29
NO20092103L (no) 2009-05-28
WO2008063867A2 (en) 2008-05-29
TN2009000189A1 (en) 2010-10-18
CL2007003182A1 (es) 2008-06-27
BRPI0719092B1 (pt) 2020-08-18
CA2670340A1 (en) 2008-05-29
ZA200903096B (en) 2010-07-28
DK2094658T3 (da) 2012-02-13
HK1134089A1 (en) 2010-04-16
EA015627B1 (ru) 2011-10-31

Similar Documents

Publication Publication Date Title
ATE538091T1 (de) Tetrahydrocyclopentaäbüindolverbindungen als androgenrezeptormodulatoren
ATE537157T1 (de) Substituierte phenoxy-n-alkylierte thiazoledindione als östrogenassoziierte rezeptor-alpha-modulatoren
BRPI0813653A2 (pt) Compostos de imidazotiazol moduladores de sirtuína
BRPI0813651A2 (pt) Compostos de tiazolopiridina moduladores de sirtuína
DE602007006531D1 (de) Pyrazin-2-carboxamid-derivate als cb2-rezeptormodulatoren
DE602008003116D1 (de) 8-oxychinolinderivate als modulatoren des bradykinin-b2-rezeptors
BRPI0815042A2 (pt) Compostos de pirazol
DE602007008222D1 (de) Diazepanderivate als modulatoren von chemokinrezeptoren
ATE502948T1 (de) Substituierte bicyclolactamverbindungen
ATE509022T1 (de) Nikotin-acetylcholin-rezeptorsubtyp-selektive diazabicycloalkanamide
BRPI0907844A2 (pt) moduladores seletivos do receptor de andrógeno
BRPI0921815A2 (pt) compostos receptores de apj
DK2014652T3 (da) Aktiveringsmiddel til peroxisom-proliferator-aktiveret receptor
DK2288375T3 (da) Pegylerede insulin-lispro-forbindelser
BRPI0920707A2 (pt) compostos
BRPI0813500A2 (pt) Compostos antivirais
DK2242759T3 (da) Forbindelser
DK2176220T3 (da) Pyrrolidin-2-on-derivater som androgenreceptormodulatorer.
BRPI0811264A2 (pt) Compostos
DK2297100T3 (da) Tetrahydrocyclopenta[b]indol-androgenreceptor-modulatorer
BRPI0914942A2 (pt) Compostos de oxindol
DK2323972T3 (da) C7-fluor-substituerede tetracylinforbindelser
DK2297162T3 (da) Forbindelser
BRPI0809996A2 (pt) Compostos
BRPI0814424A2 (pt) Compostos heterociclila